The effect of dietary lipid quality in early life on serum LysoPC(18:2) levels and their association with adult blood glucose levels in intrauterine growth restricted rats

Andrea Kodde1*, Mona Mischke1, Maryam Rakhshandehroo1, Jenny Voggel2, Gregor Fink2, Eva Nüsken2, Manfred Rauh3, Eline M. van der Beek4, Jörg Dötsch2 and Kai-Dietrich Nüsken2

Abstract

Being born small-for-gestational-age, especially with subsequent catch-up growth, is associated with impaired metabolic health in later-life. We previously showed that a postnatal diet with an adapted lipid droplet structure can ameliorate some of the adverse metabolic consequences in intrauterine growth-restricted (IUGR) rats. The aim of the present work was to explore possible underlying mechanism(s) and potential biomarkers. To this end, serum metabolomics was performed in postnatal day (PN) 42 and PN96 samples of the above-mentioned rat offspring, born after uterine vasculature ligation. Blood samples were collected at PN42, directly after a postnatal dietary intervention with either complex lipid matrix (CLM) or control (CTRL) diet, and at PN96 after a subsequent western-style diet (WSD). Offspring of Non-operated (NOP) dams fed CTRL in early life were included as control group. In the PN42 metabolomics data, 11 co-abundance modules of metabolites were identified, of which four were significantly correlated to adult blood glucose levels at PN96. Further analyses showed that Lysophosphatidylcholine(18:2) (LysoPC(18:2)) levels were reduced by ligation (p < 0.01) and restored in CLM fed animals (p < 0.05). LysoPC(18:2) levels at PN42 correlated inversely with adult blood glucose levels. These data indicate that early-life LysoPC(18:2) blood levels may predict adult blood glucose levels and are affected by a postnatal diet with an adapted lipid droplet structure in IUGR offspring.

Keywords: Metabolomics, Lysophosphatidylcholine, Intrauterine growth restriction, Postnatal diet, Blood glucose, Diabetes susceptibility, Milk fat globule membrane

Introduction

The early-life environment is essentially linked to adult metabolic health and obesity risk, and potential underlying mechanisms are manifold [1]. Low birth weight, specifically when followed by subsequent catch-up growth, is associated with increased risk for later-life obesity and impaired glucose tolerance [2–4]. Intrauterine growth-restriction (IUGR) is a major cause of low birth weight [5]. In line with this, rat offspring born after IUGR have a lower birthweight, accelerated postnatal growth, increased adiposity, and impaired glucose tolerance in adulthood [6]. Nutritional interventions starting in early-life, before the onset of an adverse phenotype, may reduce the risk for later-life obesity and impaired glucose tolerance. Indeed, exposure in postnatal life to a diet with a so-called complex lipid matrix (CLM, Nuturis®), i.e. comprising large, (milk)phospholipid coated lipid droplets, has been shown to ameliorate some of the adverse
metabolic consequences of IUGR, such as relative visceral adiposity, high blood glucose and triglyceride levels [7]. The CLM is inspired by the architecture of human milk lipid droplets, which are larger compared to those in regular infant milk formula (IMF) and enveloped by a milk fat globule membrane (MFGM) [8].

Part of the beneficial effect of the CLM may be explained by differences in tissue fat handling and postprandial kinetics, as indicated by earlier experiments in healthy mice and men [9, 10]. The aim of the present work was to further explore potential mechanisms and identify biomarkers underlying the beneficial effects of postnatal exposure to CLM on adult visceral adiposity, blood glucose and triglyceride levels in IUGR rats [7]. We hypothesized that differences in adult adiposity, blood glucose and triglyceride levels might arise from or could be predicted by differences in metabolites directly after exposure to the CLM. Therefore, serum metabolites were analyzed, and comprehensive data analysis was performed on collected data.

Methods

Study design

Samples and data used for this study where collected as part of a larger study, of which the phenotypic and physiological data were published previously, including a detailed description of the complete animal study design [7]. The design of the three groups, which were the focus of the present study was as follows, IUGR was induced by bilateral ligation (LIG) of uterine arteries and veins in pregnant Wistar HAN rats (Charles River Wiga Deutschland GmbH). Offspring of non-operated (NOP) dams was included as control group. All pups were nursed by NOP dams, which were fed American Institute of Nutrition-93Growth (AIN-93G) diet until PN15 and then either the control (CTRL) or CLM diet until litters were weaned at PN21 (Fig. 1). Weaned males continued their diet until PN42, followed by a Western-style diet (WSD) challenge (39 en% fat) until PN96. The resulting experimental groups which were the focus of this study were, NOP-CTRL (n = 9), LIG-CTRL (n = 7) and LIG-CLM (n = 8). The early diets (PN15-42) contained 28.3% (w/w) CTRL or CLM infant formula powder and were provided as dough balls in the home cage as described before [7, 8]; for dietary composition see Additional file 1: Table S1. The CLM diet contained large lipid droplets coated with milk-phospholipids [8].

Physiological parameters

Whole blood was collected after an overnight fast at PN42 and PN96. Blood glucose levels were assessed using ABL 800 FLEX (Radiometer GmbH, Willich, Germany), serum triglyceride levels determined by routine clinical laboratory procedure, and visceral adiposity at PN92 by means of micro-computerized tomography (μCT, LaTheta LCT-100; Aloka Co. LTD., Tokyo, Japan), as described [7].

Metabolomics analyses

PN42 and PN96 serum metabolite profiles were determined with tandem mass spectrometry using a Metabolomics AbsoluteIDQ® p180 96 AB Sciex Edition Kit (Biocrates, Innsbruck, Austria) as described [11]. Results below limit of detection (LOD) were set at LOD/2, results below lower limit of quantification (LLOQ) were set at (LOD + LLOQ)/2, results above upper limit of quantification (ULOQ) were set to ULOQ. Raw data are reported in Additional file 2.

Data analyses

Metabolites with >50% missing values or zero within-group variance for all groups were excluded. On the resulting metabolomics data set, weighted correlation network analysis (WGCNA) was performed for data

Fig. 1  Study design. The group size was dependent on the available blood samples which was affected by the small amounts of the blood samples. The reported group size only included the animals of which all data was available. IUGR: intra-uterine growth restriction, LIG: ligated group, NOP: non-operated group, PN: postnatal day, E: embryonic day
reduction, leading to co-abundance modules of highly correlated metabolites (EdgeLeap B.V., Utrecht, The Netherlands, Additional file 1 for more details). Data of all experimental groups was used for the WGCNA analyses, including the groups which were not the focus of our research question (see Additional file 3: Fig. S1A for details of all experimental groups). For each module an ‘Eigenprofile’ was calculated, representing overall abundance of the metabolites of the module. Biweight midcorrelations were calculated between ‘Eigenprofiles’ of the modules and physiological parameters at PN96 (PN92 for visceral adiposity). All analyses were performed in R 3.2.2 (2015-08-14) using the WGCNA package 1.46.

**Statistics**

Statistical differences between the focus groups were analyzed with GraphPad Prism 7.03 (GraphPad Software Inc, San Diego, US), using unpaired t-tests for each comparison (NOP-CTRL vs. LIG-CTRL and LIG-CTRL vs. LIG-CLM). Gaussian distribution was tested with the Kolmogorov–Smirnov test. Pearson’s correlations were calculated between individual metabolites and physiological outcomes. Sample size calculations were designed to detect differences in plasma glucose, triglyceride levels as well as differences in body composition in the larger study [7] and was set to at least n=8 per group. The group size was also dependent on the available blood samples which was affected by the small amounts of the blood samples. The metabolomics analyses are exploratory analyses in this study and as such not included in the power calculations.

**Results**

Since the primary aim was to explore potential mechanisms for and identify biomarkers connected to the nutritionally programmed improvements in IUGR on adult visceral adiposity, blood glucose and triglyceride levels [7], we focused on the PN42 metabolomics data, their correlation with adult visceral adiposity, blood glucose and triglyceride levels and compared results between the LIG-CTRL and LIG-CLM (CLM effect), and between NOP-CTRL and LIG-CTRL (LIG effect) groups.

**Data analyses**

Out of 192 serum metabolites detected at PN42, 170 met the indicated quality criteria and WGCNA resulted in 11 metabolite modules (Additional file 1: Table S2, and Additional file 4). Correlation analysis between the ‘Eigenprofiles’ of the metabolite modules and later-life relative visceral fat mass, blood glucose and triglyceride levels showed significant correlations between module 5 and relative visceral fat mass (r = 0.287, p = 0.033), modules 1, 4, 6 and 10 and blood glucose levels (module 1:

\[ r = -0.303, p = 0.026; \]  
module 4: \[ r = 0.271, p = 0.048; \]  
module 6: \[ r = 0.314, p = 0.021 \text{ and } module 10: \[ r = 0.371, p = 0.006. \]

and between module 4 and blood triglyceride levels \( r = -0.280, p = 0.041; \) Fig. 2a–c, Additional file 1: Table S3). All those metabolite modules (1, 4, 5, 6 and 10) were subsequently further analyzed.

**Follow up data analyses**

Serum levels of the individual metabolites from the indicated modules were tested for significant differences between the focus groups. Three metabolites of module 1, being phosphatidylcholine (PC(36:2)), LysoPC(18:1) and LysoPC(18:2), were decreased in the ligated compared to the non-operated group (LIG-CTRL v. NOP-CTRL: \( p<0.01; \) Fig. 2d–f). In turn, levels of LysoPC(18:2) were higher in the LIG-CLM compared to the LIG-CTRL \( (p<0.05), \) while LysoPC(18:1) levels tended to be higher (LIG-CTRL v. LIG-CLM: \( p = 0.07). \) Levels of these three metabolites at PN42 were individually correlated to the blood glucose levels at PN96 \( (r = -0.4 \text{ and } p<0.05 \text{ for all metabolites, Fig. 2g–i), } \) but not to blood glucose levels at PN42 (Additional file 3: Fig. S1B-D). Levels of these three metabolites in adulthood (PN96) were not correlated to blood glucose levels at PN96 (Additional file 3: Fig. S1E-G).

**Discussion**

In the present study we showed that a diet containing large, milk phospholipid coated lipid droplets restored early-life LysoPC(18:2) levels in a rat model for IUGR. While early-life (PN42) LysoPC(18:2) levels showed no association with early-life glucose levels, we did find that early-life LysoPC(18:2) levels negatively correlated to adult (PN96) basal glucose levels.

In humans, reduced LysoPC(18:2) levels were found in insulin-resistant individuals and appeared years ahead of diagnosis for Type 2 diabetes mellitus (T2D) [12, 13]. How the reduced LysoPC(18:2) levels link with T2D is unknown, but this may include disturbed hepatic phospholipid biosynthesis in the onset of insulin resistance [14]. In the current study, low LysoPC(18:2) levels correlated to elevated adult fasting blood glucose levels in IUGR rats, which might indicate a (pre)diabetic phenotype in early adulthood of fetal growth restricted animals. A direct link between LysoPCs and blood glucose levels is supported by in vitro data showing increased glucose uptake by adipocytes exposed to specific, saturated LysoPCs [15]. However, the absence of a direct correlation between LysoPC(18:2) levels and glucose levels at the same time point, both at PN42 and PN96, in our data does not support such a direct effect for LysoPC(18:2). Instead, the correlation between early-life LysoPC(18:2) levels and adult glucose levels as found in the present...
study, suggests that set points for adult glucose regulation may be established in early life, thus determining later-life susceptibility to impaired glucose tolerance. Further in vitro and in vivo experiments would be needed to confirm the role of LysoPC(18:2) in long-term regulation of blood glucose levels.

Interestingly, one recent clinical study showed that plasma LysoPC levels are affected by the early-life diet, as blood metabolome of infants fed either human milk, standard IMF or an IMF low in energy and protein, but supplemented with MFGM-fragments showed distinctly different LysoPC levels [16]. In the present study we used a postnatal diet with large lipid globules, coated with milk phospholipids, i.e. MFGM-fragments [8]. Therefore, one might argue that the increased LysoPC(18:2) levels were simply a direct consequence of the higher phospholipid intake. Approximately 30% of phospholipids in the MFGM source used were PCs with a relatively high abundance of C18:2 (~ 10% of total fatty acids [17, 18]). Although a direct link between dietary PC levels and serum LysoPC(18:2) levels cannot be ruled out, the unchanged LysoPC(18:2) levels in the control groups fed CLM in early life (Additional file 1: Table S4), argues against this.

The study had some limitations, e.g. the study was conducted in male offspring only while effects of early life nutrition on the metabolism are sex specific [19] and may therefore be different in female. Furthermore, the
results reported are exploratory findings of a larger study, which was not powered for this readout specifically, and thus may be underpowered. Follow up research, preferably in a clinical setting, would be needed to confirm the data, and affirmation of the present results would render LysoPC(18:2) an interesting biomarker, which could also be useful for the clinical setting, i.e. for risk assessment in children born small for gestational age.

Altogether, this study indicates that LysoPC(18:2) levels in early life may be a predictive biomarker for future glucose regulation and T2D risk in the IUGR population, and that these levels can be influenced by an early diet with large, phospholipid coated lipid droplets.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12986-021-00614-8.

Additional file 1. Table S1: Dietary composition. Table S2: Metabolites modules with eigenvectors and number of metabolites per module. Table S3: Correlations between relative fat mass, blood glucose and triglyceride levels at PN92-96 and metabolite modules at PN42. Table S4: Serum lysoPC(18:2) levels at PN42 in all groups.

Additional file 2. Metabolite levels per sample at PN42 and PN98 in all groups.

Additional file 3. Study design and correlation between serum metabolite and glucose levels. A) study design including all experimental groups used for the WGCNA. Intrauterine growth restriction (IUGR) was induced by bilateral ligation (ILG) in part of the dams, others were sham operated (SOP) or were not operated (NOP). 2 days after birth offspring was culled and assigned to NOP foster dams. From postnatal day (PN)15 onwards dams and litters were exposed to the different experimental diets. Offspring was weaned at PN21 and continued feeding the experimental diets until PN42 after which they were challenged with a western style diet. Correlations between plasma glucose and serum B) PC(36:2), C) LysoPC(18:1) and D) LysoPC(18:2) levels at PN42 and between plasma glucose and serum E) PC(36:2), F) LysoPC(18:1) and G) LysoPC(18:2) levels at PN98. E: embryonic day, PC: phosphatidylcholine, PN: postnatal day.

Additional file 4. Metabolite module membership of PN42 metabolomics data. Order of metabolites within a module by module membership score.

Acknowledgements
We thank Dr. Inga Teller who was one of the initiators of this project and Dr. Annemarie Oosting for making the data available for our analyses.

Authors’ contributions
AK, MM, MRak, EvdB, JD and KN designed the research; AK, MM, JV, GF, EN, MRauh and KN conducted the research; AK, MM, MRauh, and KN analysed the data; AK, MM, MRak, EvdB, JD and KN interpreted the data; AK, MM and MRak wrote the paper, all authors reviewed the paper.

Funding
Part of the work was funded by Danone Nutricia Research.

Availability of data and materials
The datasets used and/or analyzed during the current study are published as additional files or available from the corresponding author upon reasonable request.

Declarations
Ethics approval
Samples and data used for this study where collected as part of a larger animal study which was conducted in full compliance to the European Directive 2010/63/EU for the use of animals for scientific purposes and according to institutional guidelines as established by the Ethics Committee for Animal Experiments of the University of Cologne and the German Government (AZ 2011.A248).

Consent for publication
Not applicable.

Competing interests
AK, MM, and MR are employees of Danone Nutricia Research, or were (EvdB) at the time of study conduct.

Author details
1Danone Nutricia Research, Utrecht, The Netherlands. 2Department of Pediatrics and Adolescent Medicine, Medical Faculty, University Hospital Cologne, University of Cologne, Cologne, Germany. 3Department of Pediatrics and Adolescent Medicine, University Hospital Erlangen, Erlangen, Germany. 4Department of Pediatrics, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands.

Received: 18 March 2021   Accepted: 15 August 2021
Published online: 27 November 2021

References
1. Hanson MA, Gluckman PD. Early developmental conditioning of later health and disease: Physiology or pathophysiology? Physiol Rev. 2014;94(4):1027–76.
2. Mericq V, Martinez-Aguayo A, Uauy R, Iniguez G, Van der Steen M, Hekken-Koelega A. Long-term metabolic risk among children born premature or small for gestational age. Nat Rev Endocrinol. 2017;13(1):30–62.
3. Milovanovic I, Njueyen F, Dghmoun S, Chevenne D, Levy-Marchal C, Beltrand J. SGA children with moderate catch-up growth are showing the impaired insulin secretion at the age of 4. PLoS ONE. 2014;9(6):100337.
4. Harder T, Rodekamp E, Schellong K, Dudenhausen JW, Plagemann A. Birth weight and subsequent risk of type 2 diabetes: a meta-analysis. Am J Epidemiol. 2007;165(8):849–57.
5. Blencowe H, Krasevec J, de Onis M, Black RE, An X, Stevens GA, et al. National, regional, and worldwide estimates of low birthweight in 2015, with trends from 2000: a systematic analysis. Lancet Glob Health. 2019;7(7):e849–60.
6. Nusken KD, Dotsch J, Rauh M, Rascher W, Schneider H. Utero-placental insufficiency after bilateral uterine artery ligation in the rat: impact on postnatal glucose and lipid metabolism and evidence for metabolic programming of the offspring by sham operation. Endocrinology. 2008;149(3):1056–63.
7. Teller IC, Hoyer-Kuhn H, Bronneke H, Nosthoff-Horstmann P, Oosting A, Lippach G, et al. Complex lipid globules in early-life nutrition improve long-term metabolic phenotype in intra-uterine growth-restricted rats. Br J Nutr. 2018;120(7):763–76.
8. Gallier S, Vocking K, Post JA, van de Heijning B, Acton D, Van Der Beek EM, et al. A novel infant milk formula concept: mimicking the human milk fat globule structure. Colloids Surf B. 2015;136:320–39.
9. Kodde A, van der Beek EM, Phielix E, Engels G, Schipper L, Oosting A. Supramolecular structure of dietary fat in early life modulates expression
of markers for mitochondrial content and capacity in adipose tissue of adult mice. Nutr Metab (Lond). 2017;14:37.

10. Baumgartner S, van de Heijning BJM, Acton D, Mensink RP. Infant milk fat droplet size and coating affect postprandial responses in healthy adult men: a proof-of-concept study. Eur J Clin Nutr. 2017;71(9):1108–13.

11. Steinger PA, Strasser EF, Ziehe B, Eckstein R, Rauh M. Change of the metabolomic profile during short-term mononuclear cell storage. Vox Sang. 2017;112(2):163–72.

12. Wang-Sattler R, Yu Z, Herder C, Messias AC, Floegel A, He Y, et al. Novel biomarkers for pre-diabetes identified by metabolomics. Mol Syst Biol. 2012;8:615.

13. Floegel A, Stefan N, Yu Z, Muhlenbruch K, Drogan D, Joost HG, et al. Identification of serum metabolites associated with risk of type 2 diabetes using a targeted metabolomic approach. Diabetes. 2013;62(2):639–48.

14. Chang W, Hatch GM, Wang Y, Yu F, Wang M. The relationship between phospholipids and insulin resistance: from clinical to experimental studies. J Cell Mol Med. 2019;23(2):702–10.

15. Yea K, Kim J, Yoon JH, Kwon T, Kim JH, Lee BD, et al. Lysophosphatidylcholine activates adipocyte glucose uptake and lowers blood glucose levels in murine models of diabetes. J Biol Chem. 2009;284(49):33833–40.

16. He X, Parenti M, Grip T, Domellof M, Lonnerdal B, Hernell O, et al. Metabolic phenotype of breast-fed infants, and infants fed standard formula or bovine WFGM supplemented formula: a randomized controlled trial. Sci Rep. 2019;9(1):339.

17. Jensen RG. The composition of bovine milk lipids: January 1995 to December 2000. J Dairy Sci. 2002;85(2):295–350.

18. MacGibbon AKH, Taylor MW. Composition and structure of bovine milk lipids. In: Fox PF, McSweeney PLH, editors. Advanced dairy chemistry volume 2 lipids. Boston, MA: Springer; 2006. p. 1–42.

19. Dearden L, Bouret SG, Ozanne SE. Sex and gender differences in developmental programming of metabolism. Mol Metab. 2018;15:8–19.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.